Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TRAW Traws Pharma Inc.
- Stocks
- Healthcare
- NASDAQ: TRAW
Price (delayed)
$1.22
Market cap
$6.19M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$35.21
Enterprise value
-$15.15M
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has
Highlights
Traws Pharma's net income has plunged by 189% YoY but it has soared by 61% from the previous quarter
The quick ratio has surged by 185% since the previous quarter but it has declined by 18% year-on-year
Key stats
What are the main financial stats of TRAW
Market
Valuations
Earnings
Shares outstanding
5.07M
Market cap
$6.19M
Enterprise value
-$15.15M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
8.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-67.03
Revenue
$226,000
Gross profit
$226,000
Operating income
-$142.37M
Net income
-$54.67M
EBIT
-$54.67M
EBITDA
-$54.66M
Free cash flow
-$29.79M
Per share
Balance sheet
Liquidity
EPS
-$35.21
EPS diluted
-$35.21
Free cash flow per share
-$19.19
Book value per share
-$10.45
Revenue per share
$0.15
TBVPS
$16.08
Total assets
$24.96M
Total liabilities
$56.59M
Debt
$0
Equity
-$31.63M
Working capital
$13.42M
Debt to equity
0
Current ratio
2.16
Quick ratio
1.85
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
-24,186.7%
Gross margin
100%
Net margin
-24,192%
Operating margin
-62,997.3%
Return on assets
-309.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-407.1%
Return on sales
-24,192%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TRAW stock price
How has the Traws Pharma stock price performed over time
Intraday
-12.23%
1 week
-18.12%
1 month
-39%
1 year
-92.44%
YTD
-86.26%
QTD
-46.96%
Financial performance
How have Traws Pharma's revenue and profit performed over time
Revenue
$226,000
Gross profit
$226,000
Operating income
-$142.37M
Net income
-$54.67M
Gross margin
100%
Net margin
-24,192%
Traws Pharma's net income has plunged by 189% YoY but it has soared by 61% from the previous quarter
The net margin has plunged by 189% YoY but it has soared by 61% from the previous quarter
Price vs fundamentals
How does TRAW's price correlate with its fundamentals
Growth
What is Traws Pharma's growth rate over time
Valuation
What is Traws Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
8.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-67.03
The EPS has soared by 75% from the previous quarter but it has plunged by 56% YoY
The price to sales (P/S) is 96% lower than the 5-year quarterly average of 205.7 and 85% lower than the last 4 quarters average of 57.5
Efficiency
How efficient is Traws Pharma business performance
The ROS has plunged by 189% YoY but it has soared by 61% from the previous quarter
TRAW's return on assets has surged by 62% since the previous quarter
Dividends
What is TRAW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TRAW.
Financial health
How did Traws Pharma financials performed over time
TRAW's total assets is 56% smaller than its total liabilities
The quick ratio has surged by 185% since the previous quarter but it has declined by 18% year-on-year
TRAW's total assets has surged by 179% since the previous quarter and by 10% year-on-year
The debt is 100% more than the equity
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.